6 O
ADVERSE O
REACTIONS O
The O
following O
serious O
adverse O
reactions O
are O
discussed O
in O
greater O
detail O
in O
another O
section O
of O
the O
label O
[ O
see O
Warnings O
and O
Precautions O
( O
5 O
) O
] O
: O
* O
Non B-OSE_Labeled_AE
- I-OSE_Labeled_AE
infectious I-OSE_Labeled_AE
pneumonitis I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

* O
Infections B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

* O
Angioedema B-NonOSE_AE
with O
concomitant O
use O
of O
ACE O
inhibitors O
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

* O
Stomatitis B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
. O

* O
Renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
. O

* O
Impaired B-OSE_Labeled_AE
wound I-OSE_Labeled_AE
healing I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
. O

Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
the O
adverse O
reaction O
rates O
observed O
can O
not O
be O
directly O
compared O
to O
rates O
in O
other O
trials O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

EXCERPT O
: O
Advanced O
HR+ O
BC O
, O
advanced O
NET O
, O
advanced O
RCC O
: O
Most O
common O
adverse O
reactions O
( O
incidence O
> O
=30 O
% O
) O
include O
stomatitis O
, O
infections O
, O
rash O
, O
fatigue O
, O
diarrhea O
, O
edema O
, O
abdominal O
pain O
, O
nausea O
, O
fever O
, O
asthenia O
, O
cough O
, O
headache O
and O
decreased O
appetite O
. O

( O
6.1 O
, O
6.2 O
, O
6.3 O
) O
Renal O
angiomyolipoma O
with O
TSC O
: O
Most O
common O
adverse O
reaction O
( O
incidence O
> O
= O
30 O
% O
) O
is O
stomatitis O
. O

( O
6.4 O
) O
SEGA O
with O
TSC O
: O
Most O
common O
adverse O
reactions O
( O
incidence O
> O
= O
30 O
% O
) O
are O
stomatitis O
and O
respiratory O
tract O
infection O
. O

( O
6.5 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Novartis O
Pharmaceuticals O
Corporation O
at O
1-888-669-6682 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Study O
Experience O
in O
Advanced O
Hormone O
Receptor-Positive O
, O
HER2-Negative O
Breast O
Cancer O
The O
efficacy O
and O
safety O
of O
AFINITOR O
( O
10 O
mg/day O
) O
plus O
exemestane O
( O
25 O
mg/day O
) O
( O
n=485 O
) O
versus O
placebo O
plus O
exemestane O
( O
25 O
mg/day O
) O
( O
n=239 O
) O
was O
evaluated O
in O
a O
randomized O
, O
controlled O
trial O
( O
BOLERO-2 O
) O
in O
patients O
with O
advanced B-Not_AE_Candidate
or I-Not_AE_Candidate
metastatic I-Not_AE_Candidate
hormone I-Not_AE_Candidate
receptor I-Not_AE_Candidate
- I-Not_AE_Candidate
positive I-Not_AE_Candidate
, I-Not_AE_Candidate
HER I-Not_AE_Candidate
2 I-Not_AE_Candidate
- I-Not_AE_Candidate
negative I-Not_AE_Candidate
breast I-Not_AE_Candidate
cancer I-Not_AE_Candidate
. O

The O
median O
age O
of O
patients O
was O
61 O
years O
( O
range O
28-93 O
years O
) O
, O
and O
75 O
% O
were O
Caucasian O
. O

Safety O
results O
are O
based O
on O
a O
median O
follow-up O
of O
approximately O
13 O
months O
. O

The O
most O
common O
adverse O
reactions O
( O
incidence O
> O
=30 O
% O
) O
were O
stomatitis B-OSE_Labeled_AE
, O
infections B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
and O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
. O

The O
most O
common O
Grade O
3/4 O
adverse O
reactions O
( O
incidence O
> O
=2 O
% O
) O
were O
stomatitis B-OSE_Labeled_AE
, O
infections B-OSE_Labeled_AE
, O
hyperglycemia B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
, O
pneumonitis B-OSE_Labeled_AE
, O
and O
diarrhea B-OSE_Labeled_AE
. O

The O
most O
common O
laboratory O
abnormalities O
( O
incidence O
> O
=50 O
% O
) O
were O
hypercholesterolemia B-OSE_Labeled_AE
, O
hyperglycemia B-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
aspartate I-OSE_Labeled_AE
transaminase I-OSE_Labeled_AE
( I-OSE_Labeled_AE
AST I-OSE_Labeled_AE
) O
, O
anemia B-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
, O
lymphopenia B-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
alanine I-OSE_Labeled_AE
transaminase I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
) O
, O
and O
hypertriglyceridemia B-OSE_Labeled_AE
. O

The O
most O
common O
Grade O
3/4 O
laboratory O
abnormalities O
( O
incidence O
> O
= O
3 O
% O
) O
were O
lymphopenia B-OSE_Labeled_AE
, O
hyperglycemia B-OSE_Labeled_AE
, O
anemia B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
potassium I-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
AST I-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
, O
and O
thrombocytopenia B-OSE_Labeled_AE
. O

Fatal B-NonOSE_AE
adverse O
reactions O
occurred O
more O
frequently O
in O
patients O
who O
received O
AFINITOR O
plus O
exemestane O
( O
2 O
% O
) O
compared O
to O
patients O
on O
the O
placebo O
plus O
exemestane O
arm O
( O
0.4 O
% O
) O
. O

The O
rates O
of O
treatment-emergent O
adverse O
events O
resulting O
in O
permanent O
discontinuation O
were O
24 O
% O
and O
5 O
% O
for O
the O
AFINITOR O
plus O
exemestane O
and O
placebo O
plus O
exemestane O
treatment O
groups O
, O
respectively O
. O

Dose O
adjustments O
( O
interruptions O
or O
reductions O
) O
were O
more O
frequent O
among O
patients O
in O
the O
AFINITOR O
plus O
exemestane O
arm O
than O
in O
the O
placebo O
plus O
exemestane O
arm O
( O
63 O
% O
versus O
14 O
% O
) O
. O

Table O
2 O
compares O
the O
incidence O
of O
treatment-emergent O
adverse O
reactions O
reported O
with O
an O
incidence O
of O
> O
=10 O
% O
for O
patients O
receiving O
AFINITOR O
10 O
mg O
daily O
versus O
placebo O
. O

Table O
2 O
: O
Adverse O
Reactions O
Reported O
> O
=10 O
% O
of O
Patients O
with O
Advanced O
HR+ O
BC* O
Grading O
according O
to O
CTCAE O
Version O
3.0 O
* O
160 O
patients O
( O
33.2 O
% O
) O
were O
exposed O
to O
AFINITOR O
therapy O
for O
a O
period O
of O
> O
= O
32 O
weeks O
a O
Exemestane O
( O
25 O
mg/day O
) O
b O
Includes O
stomatitis B-OSE_Labeled_AE
, O
mouth B-OSE_Labeled_AE
ulceration I-OSE_Labeled_AE
, O
aphthous B-OSE_Labeled_AE
stomatitis I-OSE_Labeled_AE
, O
glossodynia B-OSE_Labeled_AE
, O
gingival B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
glossitis B-OSE_Labeled_AE
and O
lip B-OSE_Labeled_AE
ulceration I-OSE_Labeled_AE
c O
Includes O
all O
preferred O
terms O
within O
the O
' B-NonOSE_AE
infections I-NonOSE_AE
and I-NonOSE_AE
infestations I-NonOSE_AE
' I-NonOSE_AE
system O
organ O
class O
, O
the O
most O
common O
being O
nasopharyngitis B-OSE_Labeled_AE
( O
10 O
% O
) O
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
10 O
% O
) O
, O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
5 O
% O
) O
, O
pneumonia B-OSE_Labeled_AE
( O
4 O
% O
) O
, O
bronchitis B-OSE_Labeled_AE
( O
4 O
% O
) O
, O
cystitis B-OSE_Labeled_AE
( O
3 O
% O
) O
, O
sinusitis B-OSE_Labeled_AE
( O
3 O
% O
) O
, O
and O
also O
including O
candidiasis B-OSE_Labeled_AE
( O
< O
1 O
% O
) O
, O
and O
sepsis B-OSE_Labeled_AE
( O
< O
1 O
% O
) O
, O
and O
hepatitis B-OSE_Labeled_AE
C I-OSE_Labeled_AE
( O
< O
1 O
% O
) O
. O

d O
Includes O
pneumonitis B-OSE_Labeled_AE
, O
interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
, O
lung B-OSE_Labeled_AE
infiltration I-OSE_Labeled_AE
, O
and O
pulmonary B-OSE_Labeled_AE
fibrosis I-OSE_Labeled_AE
e O
Exposure O
to O
AFINITOR O
or O
placebo O
AFINITOR O
( O
10 O
mg/day O
) O
+ O
exemestane O
a O
N=482 O
Placebo O
+ O
exemestane O
a O
N=238 O
All O
Grades O
Grade O
3 O
Grade O
4 O
All O
Grades O
Grade O
3 O
Grade O
4 O
% O
% O
% O
% O
% O
% O
Any O
adverse O
reaction O
100 O
41 O
9 O
90 O
22 O
5 O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Stomatitis B-OSE_Labeled_AE
b O
67 O
8 O
0 O
11 O
0.8 O
0 O
Diarrhea B-OSE_Labeled_AE
33 O
2 O
0.2 O
18 O
0.8 O
0 O
Nausea B-OSE_Labeled_AE
29 O
0.2 O
0.2 O
28 O
1 O
0 O
Vomiting B-OSE_Labeled_AE
17 O
0.8 O
0.2 O
12 O
0.8 O
0 O
Constipation B-OSE_Labeled_AE
14 O
0.4 O
0 O
13 O
0.4 O
0 O
Dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
11 O
0 O
0 O
7 O
0 O
0 O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
36 O
4 O
0.4 O
27 O
1 O
0 O
Edema B-OSE_Labeled_AE
peripheral I-OSE_Labeled_AE
19 O
1 O
0 O
6 O
0.4 O
0 O
Pyrexia B-OSE_Labeled_AE
15 O
0.2 O
0 O
7 O
0.4 O
0 O
Asthenia B-OSE_Labeled_AE
13 O
2 O
0.2 O
4 O
0 O
0 O
Infections B-NonOSE_AE
and I-NonOSE_AE
infestations I-NonOSE_AE
Infections B-OSE_Labeled_AE
c O
50 O
4 O
1 O
25 O
2 O
0 O
Investigations B-NonOSE_AE
Weight B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
25 O
1 O
0 O
6 O
0 O
0 O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
nutrition I-NonOSE_AE
disorders I-NonOSE_AE
Decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
30 O
1 O
0 O
12 O
0.4 O
0 O
Hyperglycemia B-OSE_Labeled_AE
14 O
5 O
0.4 O
2 O
0.4 O
0 O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Arthralgia B-OSE_Labeled_AE
20 O
0.8 O
0 O
17 O
0 O
0 O
Back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
14 O
0.2 O
0 O
10 O
0.8 O
0 O
Pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
9 O
0.4 O
0 O
11 O
2 O
0 O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Dysgeusia B-OSE_Labeled_AE
22 O
0.2 O
0 O
6 O
0 O
0 O
Headache B-OSE_Labeled_AE
21 O
0.4 O
0 O
14 O
0 O
0 O
Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
Insomnia B-OSE_Labeled_AE
13 O
0.2 O
0 O
8 O
0 O
0 O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
Cough B-OSE_Labeled_AE
24 O
0.6 O
0 O
12 O
0 O
0 O
Dyspnea B-OSE_Labeled_AE
21 O
4 O
0.2 O
11 O
0.8 O
0.4 O
Epistaxis B-OSE_Labeled_AE
17 O
0 O
0 O
1 O
0 O
0 O
Pneumonitis B-OSE_Labeled_AE
d O
19 O
4 O
0.2 O
0.4 O
0 O
0 O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Rash B-OSE_Labeled_AE
39 O
1 O
0 O
6 O
0 O
0 O
Pruritus B-OSE_Labeled_AE
13 O
0.2 O
0 O
5 O
0 O
0 O
Alopecia B-OSE_Labeled_AE
10 O
0 O
0 O
5 O
0 O
0 O
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
Hot B-OSE_Labeled_AE
flush I-OSE_Labeled_AE
6 O
0 O
0 O
14 O
0 O
0 O
Median O
duration O
of O
treatment O
e O
23.9 O
weeks O
13.4 O
weeks O
Key O
observed O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
are O
presented O
in O
Table O
3 O
. O

Table O
3 O
: O
Key O
Laboratory O
Abnormalities O
Reported O
in O
> O
=10 O
% O
of O
Patients O
with O
Advanced O
HR+ O
BC O
Grading O
according O
to O
CTCAE O
Version O
3.0 O
a O
Exemestane O
( O
25 O
mg/day O
) O
b O
Reflects O
corresponding O
adverse O
drug O
reaction O
reports O
of O
anemia B-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
, O
lymphopenia B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
and O
thrombocytopenia B-OSE_Labeled_AE
( O
collectively O
as O
pancytopenia B-OSE_Labeled_AE
) O
, O
which O
occurred O
at O
lower O
frequency O
. O

Laboratory O
parameter O
AFINITOR O
( O
10 O
mg/day O
) O
+ O
exemestane O
a O
N=482 O
Placebo O
+ O
exemestane O
a O
N=238 O
All O
Grades O
Grade O
3 O
Grade O
4 O
All O
Grades O
Grade O
3 O
Grade O
4 O
% O
% O
% O
% O
% O
% O
Hematology B-NonOSE_AE
b O
Hemoglobin B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
68 O
6 O
0.6 O
40 O
0.8 O
0.4 O
WBC B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
58 O
1 O
0 O
28 O
5 O
0.8 O
Platelets B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
54 O
3 O
0.2 O
5 O
0 O
0.4 O
Lymphocytes B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
54 O
11 O
0.6 O
37 O
5 O
0.8 O
Neutrophils B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
31 O
2 O
0 O
11 O
0.8 O
0.8 O
Clinical B-NonOSE_AE
chemistry I-NonOSE_AE
Glucose B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
69 O
9 O
0.4 O
44 O
0.8 O
0.4 O
Cholesterol B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
70 O
0.6 O
0.2 O
38 O
0.8 O
0.8 O
Aspartate B-OSE_Labeled_AE
transaminase I-OSE_Labeled_AE
( I-OSE_Labeled_AE
AST I-OSE_Labeled_AE
) I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
69 O
4 O
0.2 O
45 O
3 O
0.4 O
Alanine B-OSE_Labeled_AE
transaminase I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
) I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
51 O
4 O
0.2 O
29 O
5 O
0 O
Triglycerides B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
50 O
0.8 O
0 O
26 O
0 O
0 O
Albumin B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
33 O
0.8 O
0 O
16 O
0.8 O
0 O
Potassium B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
29 O
4 O
0.2 O
7 O
1 O
0 O
Creatinine B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
24 O
2 O
0.2 O
13 O
0 O
0 O
Topical O
Prophylaxis O
for O
Stomatitis O
In O
a O
single O
arm O
study O
( O
SWISH O
; O
N=92 O
) O
in O
postmenopausal B-Not_AE_Candidate
women O
with O
hormone B-Not_AE_Candidate
receptor I-Not_AE_Candidate
- I-Not_AE_Candidate
positive I-Not_AE_Candidate
, I-Not_AE_Candidate
HER I-Not_AE_Candidate
2 I-Not_AE_Candidate
- I-Not_AE_Candidate
negative I-Not_AE_Candidate
breast I-Not_AE_Candidate
cancer I-Not_AE_Candidate
beginning O
AFINITOR O
( O
10 O
mg/day O
) O
plus O
exemestane O
( O
25 O
mg/day O
) O
, O
patients O
started O
dexamethasone O
0.5mg/5mL O
alcohol-free O
mouthwash O
( O
10 O
mL O
swished O
for O
2 O
minutes O
and O
spat O
, O
4 O
times O
daily O
for O
8 O
weeks O
) O
concurrently O
with O
AFINITOR O
and O
exemestane O
. O

No O
food O
or O
drink O
was O
to O
be O
consumed O
for O
at O
least O
1 O
hour O
after O
swishing O
and O
spitting O
the O
dexamethasone O
mouthwash O
. O

The O
primary O
objective O
of O
this O
study O
was O
to O
assess O
the O
incidence O
of O
Grade O
> O
= O
2 O
stomatitis B-NonOSE_AE
within O
8 O
weeks O
. O

The O
incidence O
of O
Grade O
> O
= O
2 O
stomatitis B-OSE_Labeled_AE
within O
8 O
weeks O
was O
2 O
% O
, O
which O
was O
lower O
than O
the O
33 O
% O
reported O
in O
the O
BOLERO-2 O
trial O
. O

The O
incidence O
of O
Grade O
1 O
stomatitis B-OSE_Labeled_AE
was O
19 O
% O
. O

No O
cases O
of O
Grade O
3 O
or O
4 O
stomatitis B-NonOSE_AE
were O
reported O
. O

Oral B-OSE_Labeled_AE
candidiasis I-OSE_Labeled_AE
was O
reported O
in O
2 O
% O
of O
patients O
in O
this O
study O
compared O
to O
0.2 O
% O
in O
the O
BOLERO-2 O
trial O
. O

6.2 O
Clinical O
Study O
Experience O
in O
Advanced O
Neuroendocrine O
Tumors O
Advanced O
Pancreatic O
Neuroendocrine O
Tumors O
( O
PNET O
) O
In O
a O
randomized O
, O
controlled O
trial O
( O
RADIANT-3 O
) O
of O
AFINITOR O
( O
n=204 O
) O
versus O
placebo O
( O
n=203 O
) O
in O
patients O
with O
advanced B-Not_AE_Candidate
PNET I-Not_AE_Candidate
the O
median O
age O
of O
patients O
was O
58 O
years O
( O
range O
20-87 O
) O
, O
79 O
% O
were O
White O
, O
and O
55 O
% O
were O
male O
. O

Patients O
on O
the O
placebo O
arm O
could O
cross O
over O
to O
open-label O
AFINITOR O
upon O
disease O
progression O
. O

The O
most O
common O
adverse O
reactions O
( O
incidence O
> O
= O
30 O
% O
) O
were O
stomatitis B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
edema B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
fever B-OSE_Labeled_AE
, O
and O
headache B-OSE_Labeled_AE
. O

The O
most O
common O
Grade O
3-4 O
adverse O
reactions O
( O
incidence O
> O
= O
5 O
% O
) O
were O
stomatitis B-OSE_Labeled_AE
and O
diarrhea B-OSE_Labeled_AE
. O

The O
most O
common O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
( O
incidence O
> O
= O
50 O
% O
) O
were O
decreased B-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
, O
hyperglycemia B-OSE_Labeled_AE
, O
alkaline B-OSE_Labeled_AE
phosphatase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
hypercholesterolemia B-OSE_Labeled_AE
, O
bicarbonate B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
and O
increased B-OSE_Labeled_AE
aspartate I-OSE_Labeled_AE
transaminase I-OSE_Labeled_AE
( I-OSE_Labeled_AE
AST I-OSE_Labeled_AE
) O
. O

The O
most O
common O
Grade O
3-4 O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
( O
incidence O
> O
= O
3 O
% O
) O
were O
hyperglycemia B-OSE_Labeled_AE
, O
lymphopenia B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
, O
hypophosphatemia B-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
alkaline I-OSE_Labeled_AE
phosphatase I-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
aspartate I-OSE_Labeled_AE
transaminase I-OSE_Labeled_AE
( I-OSE_Labeled_AE
AST I-OSE_Labeled_AE
) O
, O
potassium B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
and O
thrombocytopenia B-OSE_Labeled_AE
. O

Deaths B-NonOSE_AE
during O
double-blind O
treatment O
where O
an O
adverse O
event O
was O
the O
primary O
cause O
occurred O
in O
seven O
patients O
on O
AFINITOR O
and O
one O
patient O
on O
placebo O
. O

Causes O
of O
death B-NonOSE_AE
on O
the O
AFINITOR O
arm O
included O
one O
case O
of O
each O
of O
the O
following O
: O
acute B-NonOSE_AE
renal I-NonOSE_AE
failure I-NonOSE_AE
, O
acute B-NonOSE_AE
respiratory I-NonOSE_AE
distress I-NonOSE_AE
, O
cardiac B-NonOSE_AE
arrest I-NonOSE_AE
, O
death B-NonOSE_AE
( O
cause O
unknown O
) O
, O
hepatic B-NonOSE_AE
failure I-NonOSE_AE
, O
pneumonia B-NonOSE_AE
, O
and O
sepsis B-NonOSE_AE
. O

There O
was O
one O
death B-NonOSE_AE
due O
to O
pulmonary B-NonOSE_AE
embolism I-NonOSE_AE
on O
the O
placebo O
arm O
. O

After O
cross-over O
to O
open-label O
AFINITOR O
, O
there O
were O
three O
additional O
deaths B-NonOSE_AE
, O
one O
due O
to O
hypoglycemia B-NonOSE_AE
and O
cardiac B-NonOSE_AE
arrest I-NonOSE_AE
in O
a O
patient O
with O
insulinoma B-Not_AE_Candidate
, O
one O
due O
to O
myocardial B-NonOSE_AE
infarction I-NonOSE_AE
with O
congestive B-NonOSE_AE
heart I-NonOSE_AE
failure I-NonOSE_AE
, O
and O
the O
other O
due O
to O
sudden B-NonOSE_AE
death I-NonOSE_AE
. O

The O
rates O
of O
treatment-emergent O
adverse O
events O
resulting O
in O
permanent O
discontinuation O
were O
20 O
% O
and O
6 O
% O
for O
the O
AFINITOR O
and O
placebo O
treatment O
groups O
, O
respectively O
. O

Dose O
delay O
or O
reduction O
was O
necessary O
in O
61 O
% O
of O
everolimus O
patients O
and O
29 O
% O
of O
placebo O
patients O
. O

Grade O
3-4 O
renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
occurred O
in O
six O
patients O
in O
the O
everolimus O
arm O
and O
three O
patients O
in O
the O
placebo O
arm O
. O

Thrombotic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
included O
five O
patients O
with O
pulmonary B-OSE_Labeled_AE
embolus I-OSE_Labeled_AE
in O
the O
everolimus O
arm O
and O
one O
in O
the O
placebo O
arm O
as O
well O
as O
three O
patients O
with O
thrombosis B-OSE_Labeled_AE
in O
the O
everolimus O
arm O
and O
two O
in O
the O
placebo O
arm O
. O

Table O
4 O
compares O
the O
incidence O
of O
treatment-emergent O
adverse O
reactions O
reported O
with O
an O
incidence O
of O
> O
=10 O
% O
for O
patients O
receiving O
AFINITOR O
10 O
mg O
daily O
versus O
placebo O
. O

Table O
4 O
: O
Adverse O
Reactions O
Reported O
> O
=10 O
% O
of O
Patients O
with O
Advanced O
PNET O
Grading O
according O
to O
CTCAE O
Version O
3.0 O
a O
Includes O
stomatitis B-OSE_Labeled_AE
, O
aphthous B-OSE_Labeled_AE
stomatitis I-OSE_Labeled_AE
, O
gingival B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
/swelling/ulceration O
, O
glossitis B-OSE_Labeled_AE
, O
glossodynia B-OSE_Labeled_AE
, O
lip B-OSE_Labeled_AE
ulceration I-OSE_Labeled_AE
, O
mouth B-OSE_Labeled_AE
ulceration I-OSE_Labeled_AE
, O
tongue B-OSE_Labeled_AE
ulceration I-OSE_Labeled_AE
, O
and O
mucosal B-OSE_Labeled_AE
inflammation I-OSE_Labeled_AE
. O

b O
Includes O
diarrhea B-OSE_Labeled_AE
, O
enteritis B-OSE_Labeled_AE
, O
enterocolitis B-OSE_Labeled_AE
, O
colitis B-OSE_Labeled_AE
, O
defecation B-OSE_Labeled_AE
urgency I-OSE_Labeled_AE
, O
and O
steatorrhea B-OSE_Labeled_AE
. O

c O
Includes O
pneumonitis B-OSE_Labeled_AE
, O
interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
fibrosis I-OSE_Labeled_AE
and O
restrictive B-OSE_Labeled_AE
pulmonary I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
. O

AFINITOR O
N=204 O
Placebo O
N=203 O
All O
Grades O
Grade O
3 O
Grade O
4 O
All O
Grades O
Grade O
3 O
Grade O
4 O
% O
% O
% O
% O
% O
% O
Any O
adverse O
reaction O
100 O
49 O
13 O
98 O
32 O
8 O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Stomatitis B-OSE_Labeled_AE
a O
70 O
7 O
0 O
20 O
0 O
0 O
Diarrhea B-OSE_Labeled_AE
b O
50 O
5 O
0.5 O
25 O
3 O
0 O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
36 O
4 O
0 O
32 O
6 O
1 O
Nausea B-OSE_Labeled_AE
32 O
2 O
0 O
33 O
2 O
0 O
Vomiting B-OSE_Labeled_AE
29 O
1 O
0 O
21 O
2 O
0 O
Constipation B-OSE_Labeled_AE
14 O
0 O
0 O
13 O
0.5 O
0 O
Dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
11 O
0 O
0 O
4 O
0 O
0 O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
/ O
malaise B-OSE_Labeled_AE
45 O
3 O
0.5 O
27 O
2 O
0.5 O
Edema B-OSE_Labeled_AE
( O
general O
and O
peripheral I-OSE_Labeled_AE
) O
39 O
1 O
0.5 O
12 O
1 O
0 O
Fever B-OSE_Labeled_AE
31 O
0.5 O
0.5 O
13 O
0.5 O
0 O
Asthenia B-OSE_Labeled_AE
19 O
3 O
0 O
20 O
3 O
0 O
Infections B-NonOSE_AE
and I-NonOSE_AE
infestations I-NonOSE_AE
Nasopharyngitis B-OSE_Labeled_AE
/ O
rhinitis B-OSE_Labeled_AE
/ O
URI B-OSE_Labeled_AE
25 O
0 O
0 O
13 O
0 O
0 O
Urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
16 O
0 O
0 O
6 O
0.5 O
0 O
Investigations B-NonOSE_AE
Weight B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
28 O
0.5 O
0 O
11 O
0 O
0 O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
nutrition I-NonOSE_AE
disorders I-NonOSE_AE
Decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
30 O
1 O
0 O
18 O
1 O
0 O
Diabetes B-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
10 O
2 O
0 O
0.5 O
0 O
0 O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Arthralgia B-OSE_Labeled_AE
15 O
1 O
0.5 O
7 O
0.5 O
0 O
Back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
15 O
1 O
0 O
11 O
1 O
0 O
Pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
14 O
0.5 O
0 O
6 O
1 O
0 O
Muscle B-OSE_Labeled_AE
spasms I-OSE_Labeled_AE
10 O
0 O
0 O
4 O
0 O
0 O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Headache B-OSE_Labeled_AE
/ O
migraine B-OSE_Labeled_AE
30 O
0.5 O
0 O
15 O
1 O
0 O
Dysgeusia B-OSE_Labeled_AE
19 O
0 O
0 O
5 O
0 O
0 O
Dizziness B-OSE_Labeled_AE
12 O
0.5 O
0 O
7 O
0 O
0 O
Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
Insomnia B-OSE_Labeled_AE
14 O
0 O
0 O
8 O
0 O
0 O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
Cough B-OSE_Labeled_AE
/ O
productive B-OSE_Labeled_AE
cough I-OSE_Labeled_AE
25 O
0.5 O
0 O
13 O
0 O
0 O
Epistaxis B-OSE_Labeled_AE
22 O
0 O
0 O
1 O
0 O
0 O
Dyspnea B-OSE_Labeled_AE
/ O
dyspnea B-OSE_Labeled_AE
exertional I-OSE_Labeled_AE
20 O
2 O
0.5 O
7 O
0.5 O
0 O
Pneumonitis B-OSE_Labeled_AE
c O
17 O
3 O
0.5 O
0 O
0 O
0 O
Oropharyngeal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
11 O
0 O
0 O
6 O
0 O
0 O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
disorders I-NonOSE_AE
Rash B-OSE_Labeled_AE
59 O
0.5 O
0 O
19 O
0 O
0 O
Nail B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
22 O
0.5 O
0 O
2 O
0 O
0 O
Pruritus B-OSE_Labeled_AE
/ O
pruritus B-OSE_Labeled_AE
generalized I-OSE_Labeled_AE
21 O
0 O
0 O
13 O
0 O
0 O
Dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
/ O
xeroderma B-OSE_Labeled_AE
13 O
0 O
0 O
6 O
0 O
0 O
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
Hypertension B-OSE_Labeled_AE
13 O
1 O
0 O
6 O
1 O
0 O
Median O
duration O
of O
treatment O
( O
wks O
) O
37 O
16 O
In O
female O
patients O
aged O
18 O
to O
55 O
years O
, O
irregular B-OSE_Labeled_AE
menstruation I-OSE_Labeled_AE
occurred O
in O
5 O
of O
46 O
( O
11 O
% O
) O
AFINITOR-treated O
females O
and O
none O
of O
the O
33 O
females O
in O
the O
placebo O
group O
. O

Key O
observed O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
are O
presented O
in O
Table O
5 O
. O

Table O
5 O
: O
Key O
Laboratory O
Abnormalities O
Reported O
in O
> O
=10 O
% O
of O
Patients O
with O
Advanced O
PNET O
Grading O
according O
to O
CTCAE O
Version O
3.0 O
Laboratory O
parameter O
AFINITOR O
N=204 O
Placebo O
N=203 O
All O
Grades O
Grade O
3-4 O
All O
Grades O
Grade O
3-4 O
% O
% O
% O
% O
Hematology B-NonOSE_AE
Hemoglobin B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
86 O
15 O
63 O
1 O
Lymphocytes B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
45 O
16 O
22 O
4 O
Platelets B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
45 O
3 O
11 O
0 O
WBC B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
43 O
2 O
13 O
0 O
Neutrophils B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
30 O
4 O
17 O
2 O
Clinical B-NonOSE_AE
chemistry I-NonOSE_AE
Alkaline B-OSE_Labeled_AE
phosphatase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
74 O
8 O
66 O
8 O
Glucose B-OSE_Labeled_AE
( I-OSE_Labeled_AE
fasting I-OSE_Labeled_AE
) I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
75 O
17 O
53 O
6 O
Cholesterol B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
66 O
0.5 O
22 O
0 O
Bicarbonate B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
56 O
0 O
40 O
0 O
Aspartate B-OSE_Labeled_AE
transaminase I-OSE_Labeled_AE
( I-OSE_Labeled_AE
AST I-OSE_Labeled_AE
) I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
56 O
4 O
41 O
4 O
Alanine B-OSE_Labeled_AE
transaminase I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
) I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
48 O
2 O
35 O
2 O
Phosphate B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
40 O
10 O
14 O
3 O
Triglycerides B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
39 O
0 O
10 O
0 O
Calcium B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
37 O
0.5 O
12 O
0 O
Potassium B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
23 O
4 O
5 O
0 O
Creatinine B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
19 O
2 O
14 O
0 O
Sodium B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
16 O
1 O
16 O
1 O
Albumin B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
13 O
1 O
8 O
0 O
Bilirubin B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
10 O
1 O
14 O
2 O
Potassium B-NonOSE_AE
increased I-NonOSE_AE
7 O
0 O
10 O
0.5 O
Unresectable O
, O
Locally O
Advanced O
or O
Metastatic O
, O
Well-Differentiated O
, O
Non-Functional O
Neuroendocrine O
Tumors O
of O
Gastrointestinal O
or O
Lung O
Origin O
In O
a O
randomized O
, O
controlled O
trial O
( O
RADIANT-4 O
) O
of O
AFINITOR O
( O
n=202 O
treated O
) O
versus O
placebo O
( O
n=98 O
treated O
) O
in O
patients O
with O
advanced B-Not_AE_Candidate
non I-Not_AE_Candidate
- I-Not_AE_Candidate
functional I-Not_AE_Candidate
NET I-Not_AE_Candidate
of O
GI O
or O
lung O
origin O
, O
the O
median O
age O
of O
patients O
was O
63 O
years O
( O
range O
22-86 O
) O
, O
76 O
% O
were O
White O
, O
and O
53 O
% O
were O
female O
. O

The O
median O
duration O
of O
exposure O
to O
AFINITOR O
was O
9.3 O
months O
; O
64 O
% O
of O
patients O
were O
treated O
for O
> O
= O
6 O
months O
and O
39 O
% O
were O
treated O
for O
> O
= O
12 O
months O
. O

AFINITOR O
was O
discontinued O
for O
adverse O
reactions O
in O
29 O
% O
of O
patients O
, O
dose O
reduction O
or O
delay O
was O
required O
in O
70 O
% O
of O
AFINITOR-treated O
patients O
. O

Serious O
adverse O
reactions O
occurred O
in O
42 O
% O
of O
AFINITOR-treated O
patients O
and O
included O
3 O
fatal B-NonOSE_AE
events O
( O
cardiac B-NonOSE_AE
failure I-NonOSE_AE
, O
respiratory B-NonOSE_AE
failure I-NonOSE_AE
, O
and O
septic B-NonOSE_AE
shock I-NonOSE_AE
) O
. O

Table O
6 O
and O
Table O
7 O
summarize O
the O
incidence O
of O
adverse O
reactions O
of O
AFINITOR O
occurring O
at O
an O
incidence O
of O
> O
=10 O
% O
and O
at O
> O
=5 O
% O
absolute O
incidence O
over O
placebo O
( O
all O
Grades O
) O
or O
> O
=2 O
% O
higher O
incidence O
over O
placebo O
( O
Grade O
3 O
and O
4 O
) O
. O

Table O
6 O
: O
Adverse O
Reactions O
in O
> O
=10 O
% O
of O
AFINITOR-Treated O
Patients O
with O
Non-Functional O
NET O
of O
Gastrointestinal O
or O
Lung O
Origin O
Grading O
according O
to O
NCI O
CTCAE O
Version O
4.03 O
a O
Includes O
stomatitis B-OSE_Labeled_AE
, O
mouth B-OSE_Labeled_AE
ulceration I-OSE_Labeled_AE
, O
aphthous B-OSE_Labeled_AE
stomatitis I-OSE_Labeled_AE
, O
gingival B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
glossitis B-OSE_Labeled_AE
, O
tongue B-OSE_Labeled_AE
ulceration I-OSE_Labeled_AE
and O
mucosal B-OSE_Labeled_AE
inflammation I-OSE_Labeled_AE
. O

b O
Urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
nasopharyngitis B-OSE_Labeled_AE
, O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
lower B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
pneumonia B-OSE_Labeled_AE
, O
bronchitis B-OSE_Labeled_AE
) O
, O
abscess B-OSE_Labeled_AE
, O
pyelonephritis B-OSE_Labeled_AE
, O
septic B-OSE_Labeled_AE
shock I-OSE_Labeled_AE
and O
viral B-OSE_Labeled_AE
myocarditis I-OSE_Labeled_AE
. O

c O
Includes O
pneumonitis B-OSE_Labeled_AE
and O
interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
. O

AFINITOR O
N=202 O
Placebo O
N=98 O
All O
Grades O
Grade O
3 O
Grade O
4 O
All O
Grades O
Grade O
3 O
Grade O
4 O
% O
% O
% O
% O
% O
% O
Any O
adverse O
reaction O
99 O
57 O
12 O
89 O
21 O
7 O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Stomatitis B-OSE_Labeled_AE
a O
63 O
9 O
0 O
22 O
0 O
0 O
Diarrhea B-OSE_Labeled_AE
41 O
8 O
1 O
31 O
2 O
0 O
Nausea B-OSE_Labeled_AE
26 O
3 O
1 O
17 O
1 O
0 O
Vomiting B-OSE_Labeled_AE
15 O
4 O
0 O
12 O
2 O
0 O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
Peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
39 O
3 O
0 O
6 O
1 O
0 O
Fatigue B-OSE_Labeled_AE
37 O
4 O
1 O
36 O
1 O
0 O
Asthenia B-OSE_Labeled_AE
23 O
2 O
1 O
8 O
0 O
0 O
Pyrexia B-OSE_Labeled_AE
23 O
1 O
1 O
8 O
0 O
0 O
Infections B-NonOSE_AE
Infections B-OSE_Labeled_AE
b O
58 O
8 O
3 O
29 O
1 O
1 O
Investigations B-NonOSE_AE
Decreased B-OSE_Labeled_AE
weight I-OSE_Labeled_AE
22 O
1 O
0 O
17 O
1 O
0 O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
nutrition I-NonOSE_AE
disorders I-NonOSE_AE
Decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
22 O
1 O
0 O
17 O
1 O
0 O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Dysgeusia B-OSE_Labeled_AE
18 O
1 O
0 O
4 O
0 O
0 O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
Cough B-OSE_Labeled_AE
27 O
0 O
0 O
20 O
0 O
0 O
Dyspnea B-OSE_Labeled_AE
20 O
3 O
0 O
11 O
1 O
1 O
Pneumonitis B-OSE_Labeled_AE
c O
16 O
2 O
0 O
2 O
0 O
0 O
Epistaxis B-OSE_Labeled_AE
13 O
1 O
0 O
3 O
0 O
0 O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
disorders I-NonOSE_AE
Rash B-OSE_Labeled_AE
30 O
1 O
0 O
9 O
0 O
0 O
Pruritus B-OSE_Labeled_AE
17 O
1 O
0 O
9 O
0 O
0 O
Table O
7 O
: O
Laboratory O
Abnormalities O
in O
> O
=10 O
% O
of O
AFINITOR-Treated O
Patients O
with O
Non-Functional O
NET O
of O
Gastrointestinal O
or O
Lung O
Origin O
Grading O
according O
to O
NCI O
CTCAE O
Version O
4.03 O
AFINITOR O
N=202 O
Placebo O
N=98 O
All O
Grades O
Grade O
3 O
Grade O
4 O
All O
Grades O
Grade O
3 O
Grade O
4 O
% O
% O
% O
% O
% O
% O
Hematology B-NonOSE_AE
Anemia B-OSE_Labeled_AE
81 O
5 O
0 O
41 O
2 O
0 O
Lymphopenia B-OSE_Labeled_AE
66 O
15 O
2 O
32 O
2 O
0 O
Leukopenia B-OSE_Labeled_AE
49 O
2 O
0 O
17 O
0 O
0 O
Thrombocytopenia B-OSE_Labeled_AE
33 O
2 O
1 O
11 O
0 O
0 O
Neutropenia B-OSE_Labeled_AE
32 O
2 O
0 O
15 O
3 O
0 O
Clinical B-NonOSE_AE
chemistry I-NonOSE_AE
Hypercholesterolemia B-OSE_Labeled_AE
71 O
0 O
0 O
37 O
0 O
0 O
Elevated B-OSE_Labeled_AE
Aspartate I-OSE_Labeled_AE
transaminase I-OSE_Labeled_AE
( I-OSE_Labeled_AE
AST I-OSE_Labeled_AE
) O
57 O
1 O
1 O
34 O
2 O
0 O
Hyperglycemia B-OSE_Labeled_AE
( O
fasting O
) O
55 O
6 O
0 O
36 O
1 O
0 O
Elevated B-OSE_Labeled_AE
Alanine I-OSE_Labeled_AE
transaminase I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
) O
46 O
5 O
1 O
39 O
1 O
0 O
Hypophosphatemia B-OSE_Labeled_AE
43 O
4 O
0 O
15 O
2 O
0 O
Hypertriglyceridemia B-OSE_Labeled_AE
30 O
3 O
1 O
8 O
1 O
0 O
Hypokalemia B-OSE_Labeled_AE
27 O
4 O
2 O
12 O
3 O
0 O
Hypoalbuminemia B-OSE_Labeled_AE
18 O
0 O
0 O
8 O
0 O
0 O
6.3 O
Clinical O
Study O
Experience O
in O
Advanced O
Renal O
Cell O
Carcinoma O
The O
data O
described O
below O
reflect O
exposure O
to O
AFINITOR O
( O
n=274 O
) O
and O
placebo O
( O
n=137 O
) O
in O
a O
randomized O
, O
controlled O
trial O
( O
RECORD-1 O
) O
in O
patients O
with O
metastatic B-Not_AE_Candidate
renal I-Not_AE_Candidate
cell I-Not_AE_Candidate
carcinoma I-Not_AE_Candidate
who O
received O
prior O
treatment O
with O
sunitinib O
and/or O
sorafenib O
. O

The O
median O
age O
of O
patients O
was O
61 O
years O
( O
range O
27-85 O
) O
, O
88 O
% O
were O
Caucasian O
, O
and O
78 O
% O
were O
male O
. O

The O
median O
duration O
of O
blinded O
study O
treatment O
was O
141 O
days O
( O
range O
19-451 O
days O
) O
for O
patients O
receiving O
AFINITOR O
and O
60 O
days O
( O
range O
21-295 O
days O
) O
for O
those O
receiving O
placebo O
. O

The O
most O
common O
adverse O
reactions O
( O
incidence O
> O
=30 O
% O
) O
were O
stomatitis B-OSE_Labeled_AE
, O
infections B-OSE_Labeled_AE
, O
asthenia B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
cough B-OSE_Labeled_AE
, O
and O
diarrhea B-OSE_Labeled_AE
. O

The O
most O
common O
Grade O
3-4 O
adverse O
reactions O
( O
incidence O
> O
=3 O
% O
) O
were O
infections B-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
stomatitis B-OSE_Labeled_AE
, O
dehydration B-OSE_Labeled_AE
, O
pneumonitis B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
and O
asthenia B-OSE_Labeled_AE
. O

The O
most O
common O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
( O
incidence O
> O
=50 O
% O
) O
were O
anemia B-OSE_Labeled_AE
, O
hypercholesterolemia B-OSE_Labeled_AE
, O
hypertriglyceridemia B-OSE_Labeled_AE
, O
hyperglycemia B-OSE_Labeled_AE
, O
lymphopenia B-OSE_Labeled_AE
, O
and O
increased B-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
. O

The O
most O
common O
Grade O
3-4 O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
( O
incidence O
> O
=3 O
% O
) O
were O
lymphopenia B-OSE_Labeled_AE
, O
hyperglycemia B-OSE_Labeled_AE
, O
anemia B-OSE_Labeled_AE
, O
hypophosphatemia B-OSE_Labeled_AE
, O
and O
hypercholesterolemia B-OSE_Labeled_AE
. O

Deaths B-NonOSE_AE
due O
to O
acute B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
( O
0.7 O
% O
) O
, O
infection B-OSE_Labeled_AE
( O
0.7 O
% O
) O
, O
and O
acute B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
( O
0.4 O
% O
) O
were O
observed O
on O
the O
AFINITOR O
arm O
but O
none O
on O
the O
placebo O
arm O
. O

The O
rates O
of O
treatment-emergent O
adverse O
events O
( O
irrespective O
of O
causality O
) O
resulting O
in O
permanent O
discontinuation O
were O
14 O
% O
and O
3 O
% O
for O
the O
AFINITOR O
and O
placebo O
treatment O
groups O
, O
respectively O
. O

The O
most O
common O
adverse O
reactions O
( O
irrespective O
of O
causality O
) O
leading O
to O
treatment O
discontinuation O
were O
pneumonitis B-OSE_Labeled_AE
and O
dyspnea B-OSE_Labeled_AE
. O

Infections B-OSE_Labeled_AE
, O
stomatitis B-OSE_Labeled_AE
, O
and O
pneumonitis B-OSE_Labeled_AE
were O
the O
most O
common O
reasons O
for O
treatment O
delay O
or O
dose O
reduction O
. O

The O
most O
common O
medical O
interventions O
required O
during O
AFINITOR O
treatment O
were O
for O
infections B-OSE_Labeled_AE
, O
anemia B-OSE_Labeled_AE
, O
and O
stomatitis B-OSE_Labeled_AE
. O

Table O
8 O
compares O
the O
incidence O
of O
treatment-emergent O
adverse O
reactions O
reported O
with O
an O
incidence O
of O
> O
=10 O
% O
for O
patients O
receiving O
AFINITOR O
10 O
mg O
daily O
versus O
placebo O
. O

Within O
each O
MedDRA O
system O
organ O
class O
, O
the O
adverse O
reactions O
are O
presented O
in O
order O
of O
decreasing O
frequency O
. O

Table O
8 O
: O
Adverse O
Reactions O
Reported O
in O
at O
Least O
10 O
% O
of O
Patients O
with O
RCC O
and O
at O
a O
Higher O
Rate O
in O
the O
AFINITOR O
Arm O
than O
in O
the O
Placebo O
Arm O
Grading O
according O
to O
CTCAE O
Version O
3.0 O
a O
Stomatitis B-OSE_Labeled_AE
( O
including O
aphthous B-OSE_Labeled_AE
stomatitis I-OSE_Labeled_AE
) O
, O
and O
mouth B-OSE_Labeled_AE
and O
tongue O
ulceration I-OSE_Labeled_AE
. O

b O
Includes O
all O
preferred O
terms O
within O
the O
' B-NonOSE_AE
infections I-NonOSE_AE
and I-NonOSE_AE
infestations I-NonOSE_AE
' I-NonOSE_AE
system O
organ O
class O
, O
the O
most O
common O
being O
nasopharyngitis B-OSE_Labeled_AE
( O
6 O
% O
) O
, O
pneumonia B-OSE_Labeled_AE
( O
6 O
% O
) O
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
5 O
% O
) O
, O
bronchitis B-OSE_Labeled_AE
( O
4 O
% O
) O
, O
and O
sinusitis B-OSE_Labeled_AE
( O
3 O
% O
) O
, O
and O
also O
including O
aspergillosis B-OSE_Labeled_AE
( O
< O
1 O
% O
) O
, O
candidiasis B-OSE_Labeled_AE
( O
< O
1 O
% O
) O
, O
and O
sepsis B-OSE_Labeled_AE
( O
< O
1 O
% O
) O
. O

c O
Includes O
pneumonitis B-OSE_Labeled_AE
, O
interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
, O
lung B-OSE_Labeled_AE
infiltration I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
alveolar I-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
, O
and O
alveolitis B-OSE_Labeled_AE
. O

AFINITOR O
10 O
mg/day O
N=274 O
Placebo O
N=137 O
All O
Grades O
Grade O
3 O
Grade O
4 O
All O
Grades O
Grade O
3 O
Grade O
4 O
% O
% O
% O
% O
% O
% O
Any O
a O
dverse O
r O
eaction O
97 O
52 O
13 O
93 O
23 O
5 O
Gastrointestinal B-NonOSE_AE
d I-NonOSE_AE
isorders I-NonOSE_AE
Stomatitis B-OSE_Labeled_AE
a O
44 O
4 O
< O
1 O
8 O
0 O
0 O
Diarrhea B-OSE_Labeled_AE
30 O
1 O
0 O
7 O
0 O
0 O
Nausea B-OSE_Labeled_AE
26 O
1 O
0 O
19 O
0 O
0 O
Vomiting B-OSE_Labeled_AE
20 O
2 O
0 O
12 O
0 O
0 O
Infections B-NonOSE_AE
and I-NonOSE_AE
i I-NonOSE_AE
nfestations I-NonOSE_AE
b O
37 O
7 O
3 O
18 O
1 O
0 O
General B-NonOSE_AE
d I-NonOSE_AE
isorders I-NonOSE_AE
and I-NonOSE_AE
a I-NonOSE_AE
dministration I-NonOSE_AE
s I-NonOSE_AE
ite I-NonOSE_AE
c I-NonOSE_AE
onditions I-NonOSE_AE
Asthenia B-OSE_Labeled_AE
33 O
3 O
< O
1 O
23 O
4 O
0 O
Fatigue B-OSE_Labeled_AE
31 O
5 O
0 O
27 O
3 O
< O
1 O
Edema B-OSE_Labeled_AE
peripheral I-OSE_Labeled_AE
25 O
< O
1 O
0 O
8 O
< O
1 O
0 O
Pyrexia B-OSE_Labeled_AE
20 O
< O
1 O
0 O
9 O
0 O
0 O
Mucosal B-OSE_Labeled_AE
inflammation I-OSE_Labeled_AE
19 O
1 O
0 O
1 O
0 O
0 O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
t I-NonOSE_AE
horacic I-NonOSE_AE
and I-NonOSE_AE
m I-NonOSE_AE
ediastinal I-NonOSE_AE
d I-NonOSE_AE
isorders I-NonOSE_AE
Cough B-OSE_Labeled_AE
30 O
< O
1 O
0 O
16 O
0 O
0 O
Dyspnea B-OSE_Labeled_AE
24 O
6 O
1 O
15 O
3 O
0 O
Epistaxis B-OSE_Labeled_AE
18 O
0 O
0 O
0 O
0 O
0 O
Pneumonitis B-OSE_Labeled_AE
c O
14 O
4 O
0 O
0 O
0 O
0 O
Skin B-NonOSE_AE
and I-NonOSE_AE
s I-NonOSE_AE
ubcutaneous I-NonOSE_AE
t I-NonOSE_AE
issue I-NonOSE_AE
d I-NonOSE_AE
isorders I-NonOSE_AE
Rash B-OSE_Labeled_AE
29 O
1 O
0 O
7 O
0 O
0 O
Pruritus B-OSE_Labeled_AE
14 O
< O
1 O
0 O
7 O
0 O
0 O
Dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
13 O
< O
1 O
0 O
5 O
0 O
0 O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
n I-NonOSE_AE
utrition I-NonOSE_AE
d I-NonOSE_AE
isorders I-NonOSE_AE
Anorexia B-OSE_Labeled_AE
25 O
1 O
0 O
14 O
< O
1 O
0 O
Nervous B-NonOSE_AE
s I-NonOSE_AE
ystem I-NonOSE_AE
d I-NonOSE_AE
isorders I-NonOSE_AE
Headache B-OSE_Labeled_AE
19 O
< O
1 O
< O
1 O
9 O
< O
1 O
0 O
Dysgeusia B-OSE_Labeled_AE
10 O
0 O
0 O
2 O
0 O
0 O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
c I-NonOSE_AE
onnective I-NonOSE_AE
t I-NonOSE_AE
issue I-NonOSE_AE
d I-NonOSE_AE
isorders I-NonOSE_AE
Pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
10 O
1 O
0 O
7 O
0 O
0 O
Medi O
an O
d O
uration O
of O
t O
reatment O
( O
d O
) O
141 O
60 O
Other O
notable O
adverse O
reactions O
occurring O
more O
frequently O
with O
AFINITOR O
than O
with O
placebo O
, O
but O
with O
an O
incidence O
of O
< O
10 O
% O
include O
: O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
: O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
9 O
% O
) O
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
( O
8 O
% O
) O
, O
hemorrhoids B-OSE_Labeled_AE
( O
5 O
% O
) O
, O
dysphagia B-OSE_Labeled_AE
( O
4 O
% O
) O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
: O
Weight B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
( O
9 O
% O
) O
, O
chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
5 O
% O
) O
, O
chills B-OSE_Labeled_AE
( O
4 O
% O
) O
, O
impaired B-OSE_Labeled_AE
wound I-OSE_Labeled_AE
healing I-OSE_Labeled_AE
( O
< O
1 O
% O
) O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
: O
Pleural B-OSE_Labeled_AE
effusion I-OSE_Labeled_AE
( O
7 O
% O
) O
, O
pharyngolaryngeal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
4 O
% O
) O
, O
rhinorrhea B-OSE_Labeled_AE
( O
3 O
% O
) O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
Hand B-OSE_Labeled_AE
- I-OSE_Labeled_AE
foot I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
( O
reported O
as O
palmar B-OSE_Labeled_AE
- I-OSE_Labeled_AE
plantar I-OSE_Labeled_AE
erythrodysesthesia I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
) O
( O
5 O
% O
) O
, O
nail B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
( O
5 O
% O
) O
, O
erythema B-OSE_Labeled_AE
( O
4 O
% O
) O
, O
onychoclasis B-OSE_Labeled_AE
( O
4 O
% O
) O
, O
skin B-OSE_Labeled_AE
lesion I-OSE_Labeled_AE
( O
4 O
% O
) O
, O
acneiform B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
( O
3 O
% O
) O
, O
angioedema B-OSE_Labeled_AE
( O
< O
1 O
% O
) O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
nutrition I-NonOSE_AE
disorders I-NonOSE_AE
: O
Exacerbation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
pre I-OSE_Labeled_AE
- I-OSE_Labeled_AE
existing I-OSE_Labeled_AE
diabetes I-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
( O
2 O
% O
) O
, O
new B-OSE_Labeled_AE
onset I-OSE_Labeled_AE
of I-OSE_Labeled_AE
diabetes I-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
( O
< O
1 O
% O
) O
Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
: O
Insomnia B-OSE_Labeled_AE
( O
9 O
% O
) O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
Dizziness B-OSE_Labeled_AE
( O
7 O
% O
) O
, O
paresthesia B-OSE_Labeled_AE
( O
5 O
% O
) O
Eye B-NonOSE_AE
disorders I-NonOSE_AE
: O
Eyelid B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
( O
4 O
% O
) O
, O
conjunctivitis B-OSE_Labeled_AE
( O
2 O
% O
) O
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
: O
Hypertension B-OSE_Labeled_AE
( O
4 O
% O
) O
, O
deep B-OSE_Labeled_AE
vein I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
( O
< O
1 O
% O
) O
Renal B-NonOSE_AE
and I-NonOSE_AE
urinary I-NonOSE_AE
disorders I-NonOSE_AE
: O
Renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
( O
3 O
% O
) O
Cardiac B-NonOSE_AE
disorders I-NonOSE_AE
: O
Tachycardia B-OSE_Labeled_AE
( O
3 O
% O
) O
, O
congestive B-OSE_Labeled_AE
cardiac I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
( O
1 O
% O
) O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
Jaw B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
3 O
% O
) O
Hematologic B-NonOSE_AE
disorders I-NonOSE_AE
: O
Hemorrhage B-OSE_Labeled_AE
( O
3 O
% O
) O
Key O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
are O
presented O
in O
Table O
9 O
. O

Table O
9 O
: O
Key O
Laboratory O
Abnormalities O
Reported O
in O
Patients O
with O
RCC O
at O
a O
Higher O
Rate O
in O
the O
AFINITOR O
Arm O
than O
the O
Placebo O
Arm O
Grading O
according O
to O
CTCAE O
Version O
3.0 O
a O
Reflects O
corresponding O
adverse O
drug O
reaction O
reports O
of O
anemia B-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
, O
lymphopenia B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
and O
thrombocytopenia B-OSE_Labeled_AE
( O
collectively O
pancytopenia B-OSE_Labeled_AE
) O
, O
which O
occurred O
at O
lower O
frequency O
. O

Laboratory O
p O
arameter O
AFINITOR O
10 O
mg/day O
N=274 O
Placebo O
N=137 O
All O
Grades O
Grade O
3 O
Grade O
4 O
All O
Grades O
Grade O
3 O
Grade O
4 O
% O
% O
% O
% O
% O
% O
Hematology B-NonOSE_AE
a O
Hemoglobin B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
92 O
12 O
1 O
79 O
5 O
< O
1 O
Lymphocytes B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
51 O
16 O
2 O
28 O
5 O
0 O
Platelets B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
23 O
1 O
0 O
2 O
0 O
< O
1 O
Neutrophils B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
14 O
0 O
< O
1 O
4 O
0 O
0 O
Clinical B-NonOSE_AE
c I-NonOSE_AE
hemistry I-NonOSE_AE
Cholesterol B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
77 O
4 O
0 O
35 O
0 O
0 O
Triglycerides B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
73 O
< O
1 O
0 O
34 O
0 O
0 O
Glucose B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
57 O
15 O
< O
1 O
25 O
1 O
0 O
Creatinine B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
50 O
1 O
0 O
34 O
0 O
0 O
Phosphate B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
37 O
6 O
0 O
8 O
0 O
0 O
Aspartate B-OSE_Labeled_AE
transaminase I-OSE_Labeled_AE
( I-OSE_Labeled_AE
AST I-OSE_Labeled_AE
) I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
25 O
< O
1 O
< O
1 O
7 O
0 O
0 O
Alanine B-OSE_Labeled_AE
transaminase I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
) I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
21 O
1 O
0 O
4 O
0 O
0 O
Bilirubin B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
3 O
< O
1 O
< O
1 O
2 O
0 O
0 O
6.4 O
Clinical O
Study O
Experience O
in O
Renal O
Angiomyolipoma O
with O
Tuberous O
Sclerosis O
Complex O
The O
data O
described O
below O
are O
based O
on O
a O
randomized O
( O
2:1 O
) O
, O
double-blind O
, O
placebo-controlled O
trial O
( O
EXIST-2 O
) O
of O
AFINITOR O
in O
118 O
patients O
with O
renal B-Not_AE_Candidate
angiomyolipoma I-Not_AE_Candidate
as I-Not_AE_Candidate
a I-Not_AE_Candidate
feature I-Not_AE_Candidate
of I-Not_AE_Candidate
TSC I-Not_AE_Candidate
( O
n=113 O
) O
or O
sporadic B-Not_AE_Candidate
lymphangioleiomyomatosis I-Not_AE_Candidate
( O
n=5 O
) O
. O

The O
median O
age O
of O
patients O
was O
31 O
years O
( O
range O
18 O
to O
61 O
years O
) O
, O
89 O
% O
were O
Caucasian O
, O
and O
34 O
% O
were O
male O
. O

The O
median O
duration O
of O
blinded O
study O
treatment O
was O
48 O
weeks O
( O
range O
2 O
to O
115 O
weeks O
) O
for O
patients O
receiving O
AFINITOR O
and O
45 O
weeks O
( O
range O
9 O
to O
115 O
weeks O
) O
for O
those O
receiving O
placebo O
. O

The O
most O
common O
adverse O
reaction O
reported O
for O
AFINITOR O
( O
incidence O
> O
=30 O
% O
) O
was O
stomatitis B-OSE_Labeled_AE
. O

The O
most O
common O
Grade O
3-4 O
adverse O
reactions O
( O
incidence O
> O
=2 O
% O
) O
were O
stomatitis B-OSE_Labeled_AE
and O
amenorrhea B-OSE_Labeled_AE
. O

The O
most O
common O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
( O
incidence O
> O
=50 O
% O
) O
were O
hypercholesterolemia B-OSE_Labeled_AE
, O
hypertriglyceridemia B-OSE_Labeled_AE
, O
and O
anemia B-OSE_Labeled_AE
. O

The O
most O
common O
Grade O
3-4 O
laboratory B-NonOSE_AE
abnormality I-NonOSE_AE
( O
incidence O
> O
=3 O
% O
) O
was O
hypophosphatemia B-OSE_Labeled_AE
. O

The O
rate O
of O
adverse O
reactions O
resulting O
in O
permanent O
discontinuation O
was O
3.8 O
% O
in O
the O
AFINITOR-treated O
patients O
. O

Adverse O
reactions O
leading O
to O
permanent O
discontinuation O
in O
the O
AFINITOR O
arm O
were O
hypersensitivity B-OSE_Labeled_AE
/ O
angioedema B-OSE_Labeled_AE
/ O
bronchospasm B-OSE_Labeled_AE
, O
convulsion B-OSE_Labeled_AE
, O
and O
hypophosphatemia B-OSE_Labeled_AE
. O

Dose O
adjustments O
( O
interruptions O
or O
reductions O
) O
due O
to O
adverse O
reactions O
occurred O
in O
52 O
% O
of O
AFINITOR-treated O
patients O
. O

The O
most O
common O
adverse O
reaction O
leading O
to O
AFINITOR O
dose O
adjustment O
was O
stomatitis B-OSE_Labeled_AE
. O

Table O
10 O
compares O
the O
incidence O
of O
adverse O
reactions O
reported O
with O
an O
incidence O
of O
> O
=10 O
% O
for O
patients O
receiving O
AFINITOR O
and O
occurring O
more O
frequently O
with O
AFINITOR O
than O
with O
placebo O
. O

Laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
are O
described O
separately O
in O
Table O
11 O
. O

Table O
10 O
: O
Adverse O
Reactions O
Reported O
in O
> O
=10 O
% O
of O
AFINITOR-treated O
Patients O
with O
Renal O
Angiomyolipoma O
Grading O
according O
to O
CTCAE O
Version O
3.0 O
a O
Includes O
stomatitis B-OSE_Labeled_AE
, O
aphthous B-OSE_Labeled_AE
stomatitis I-OSE_Labeled_AE
, O
mouth B-OSE_Labeled_AE
ulceration I-OSE_Labeled_AE
, O
gingival B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
glossitis B-OSE_Labeled_AE
, O
and O
glossodynia B-OSE_Labeled_AE
. O

AFINITOR O
N=79 O
Placebo O
N=39 O
All O
Grades O
% O
Grade O
3 O
% O
Grade O
4 O
% O
All O
Grades O
% O
Grade O
3 O
% O
Grade O
4 O
% O
Any O
adverse O
reaction O
100 O
25 O
5 O
97 O
8 O
5 O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Stomatitis B-OSE_Labeled_AE
a O
78 O
6 O
0 O
23 O
0 O
0 O
Vomiting B-OSE_Labeled_AE
15 O
0 O
0 O
5 O
0 O
0 O
Diarrhea B-OSE_Labeled_AE
14 O
0 O
0 O
5 O
0 O
0 O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
Peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
13 O
0 O
0 O
8 O
0 O
0 O
Infections B-NonOSE_AE
and I-NonOSE_AE
infestations I-NonOSE_AE
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
11 O
0 O
0 O
5 O
0 O
0 O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Arthralgia B-OSE_Labeled_AE
13 O
0 O
0 O
5 O
0 O
0 O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
Cough B-OSE_Labeled_AE
20 O
0 O
0 O
13 O
0 O
0 O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Acne B-OSE_Labeled_AE
22 O
0 O
0 O
5 O
0 O
0 O
Amenorrhea B-OSE_Labeled_AE
occurred O
in O
15 O
% O
of O
AFINITOR-treated O
females O
( O
8 O
of O
52 O
) O
and O
4 O
% O
( O
1 O
of O
26 O
) O
of O
females O
in O
the O
placebo O
group O
. O

Other O
adverse O
reactions O
involving O
the O
female O
reproductive O
system O
were O
menorrhagia B-OSE_Labeled_AE
( O
10 O
% O
) O
, O
menstrual B-OSE_Labeled_AE
irregularities I-OSE_Labeled_AE
( O
10 O
% O
) O
, O
and O
vaginal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
( O
8 O
% O
) O
. O

The O
following O
additional O
adverse O
reactions O
occurred O
in O
less O
than O
10 O
% O
of O
AFINITOR-treated O
patients O
: O
epistaxis B-OSE_Labeled_AE
( O
9 O
% O
) O
, O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
( O
6 O
% O
) O
, O
otitis B-OSE_Labeled_AE
media I-OSE_Labeled_AE
( O
6 O
% O
) O
, O
depression B-OSE_Labeled_AE
( O
5 O
% O
) O
, O
abnormal B-OSE_Labeled_AE
taste I-OSE_Labeled_AE
( O
5 O
% O
) O
, O
increased B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
luteinizing I-OSE_Labeled_AE
hormone I-OSE_Labeled_AE
( I-OSE_Labeled_AE
LH I-OSE_Labeled_AE
) I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
( O
4 O
% O
) O
, O
increased B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
follicle I-OSE_Labeled_AE
stimulating I-OSE_Labeled_AE
hormone I-OSE_Labeled_AE
( I-OSE_Labeled_AE
FSH I-OSE_Labeled_AE
) I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
( O
3 O
% O
) O
, O
hypersensitivity B-OSE_Labeled_AE
( O
3 O
% O
) O
, O
ovarian B-OSE_Labeled_AE
cyst I-OSE_Labeled_AE
( O
3 O
% O
) O
, O
pneumonitis B-OSE_Labeled_AE
( O
1 O
% O
) O
, O
and O
angioedema B-OSE_Labeled_AE
( O
1 O
% O
) O
. O

Table O
11 O
: O
Key O
Laboratory O
Abnormalities O
Reported O
in O
AFINITOR-treated O
Patients O
with O
Renal O
Angiomyolipoma O
Grading O
according O
to O
CTCAE O
Version O
3.0 O
AFINITOR O
N=79 O
Placebo O
N=39 O
All O
Grades O
% O
Grade O
3 O
% O
Grade O
4 O
% O
All O
Grades O
% O
Grade O
3 O
% O
Grade O
4 O
% O
Hematology B-NonOSE_AE
Anemia B-OSE_Labeled_AE
61 O
0 O
0 O
49 O
0 O
0 O
Leucopenia B-OSE_Labeled_AE
37 O
0 O
0 O
21 O
0 O
0 O
Neutropenia B-NonOSE_AE
25 O
0 O
1 O
26 O
0 O
0 O
Lymphopenia B-OSE_Labeled_AE
20 O
1 O
0 O
8 O
0 O
0 O
Thrombocytopenia B-OSE_Labeled_AE
19 O
0 O
0 O
3 O
0 O
0 O
Clinical B-NonOSE_AE
chemistry I-NonOSE_AE
Hypercholesterolemia B-OSE_Labeled_AE
85 O
1 O
0 O
46 O
0 O
0 O
Hypertriglyceridemia B-OSE_Labeled_AE
52 O
0 O
0 O
10 O
0 O
0 O
Hypophosphatemia B-OSE_Labeled_AE
49 O
5 O
0 O
15 O
0 O
0 O
Alkaline B-OSE_Labeled_AE
phosphatase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
32 O
1 O
0 O
10 O
0 O
0 O
Elevated B-OSE_Labeled_AE
aspartate I-OSE_Labeled_AE
transaminase I-OSE_Labeled_AE
( I-OSE_Labeled_AE
AST I-OSE_Labeled_AE
) O
23 O
1 O
0 O
8 O
0 O
0 O
Elevated B-OSE_Labeled_AE
alanine I-OSE_Labeled_AE
transaminase I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
) O
20 O
1 O
0 O
15 O
0 O
0 O
Fasting B-OSE_Labeled_AE
hyperglycemia I-OSE_Labeled_AE
14 O
0 O
0 O
8 O
0 O
0 O
Updated O
safety O
information O
from O
112 O
patients O
treated O
with O
AFINITOR O
for O
a O
median O
duration O
of O
3.9 O
years O
identified O
the O
following O
additional O
adverse O
reactions O
and O
key O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
: O
increased B-OSE_Labeled_AE
partial I-OSE_Labeled_AE
thromboplastin I-OSE_Labeled_AE
time I-OSE_Labeled_AE
( O
63 O
% O
) O
, O
increased B-OSE_Labeled_AE
prothrombin I-OSE_Labeled_AE
time I-OSE_Labeled_AE
( O
40 O
% O
) O
, O
decreased B-OSE_Labeled_AE
fibrinogen I-OSE_Labeled_AE
( O
38 O
% O
) O
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
31 O
% O
) O
, O
proteinuria B-OSE_Labeled_AE
( O
18 O
% O
) O
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
16 O
% O
) O
, O
pruritus B-OSE_Labeled_AE
( O
12 O
% O
) O
, O
gastroenteritis B-OSE_Labeled_AE
( O
12 O
% O
) O
, O
myalgia B-OSE_Labeled_AE
( O
11 O
% O
) O
, O
and O
pneumonia B-OSE_Labeled_AE
( O
10 O
% O
) O
. O

6.5 O
Clinical O
Study O
Experience O
in O
Subependymal O
Giant O
Cell O
Astrocytoma O
with O
Tuberous O
Sclerosis O
Complex O
The O
data O
described O
below O
are O
based O
on O
a O
randomized O
( O
2:1 O
) O
, O
double-blind O
, O
placebo-controlled O
trial O
( O
EXIST-1 O
) O
of O
AFINITOR O
in O
117 O
patients O
with O
subependymal B-Not_AE_Candidate
giant I-Not_AE_Candidate
cell I-Not_AE_Candidate
astrocytoma I-Not_AE_Candidate
( I-Not_AE_Candidate
SEGA I-Not_AE_Candidate
) I-Not_AE_Candidate
and I-Not_AE_Candidate
tuberous I-Not_AE_Candidate
sclerosis I-Not_AE_Candidate
complex I-Not_AE_Candidate
( I-Not_AE_Candidate
TSC I-Not_AE_Candidate
) O
. O

The O
median O
age O
of O
patients O
was O
9.5 O
years O
( O
range O
0.8 O
to O
26 O
years O
) O
, O
93 O
% O
were O
Caucasian O
, O
and O
57 O
% O
were O
male O
. O

The O
median O
duration O
of O
blinded O
study O
treatment O
was O
52 O
weeks O
( O
range O
24 O
to O
89 O
weeks O
) O
for O
patients O
receiving O
AFINITOR O
and O
47 O
weeks O
( O
range O
14 O
to O
88 O
weeks O
) O
for O
those O
receiving O
placebo O
. O

The O
most O
common O
adverse O
reactions O
reported O
for O
AFINITOR O
( O
incidence O
> O
= O
30 O
% O
) O
were O
stomatitis B-OSE_Labeled_AE
and O
respiratory B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
. O

The O
most O
common O
Grade O
3-4 O
adverse O
reactions O
( O
incidence O
> O
=2 O
% O
) O
were O
stomatitis B-OSE_Labeled_AE
, O
pyrexia B-OSE_Labeled_AE
, O
pneumonia B-OSE_Labeled_AE
, O
gastroenteritis B-OSE_Labeled_AE
, O
aggression B-OSE_Labeled_AE
, O
agitation B-OSE_Labeled_AE
, O
and O
amenorrhea B-OSE_Labeled_AE
. O

The O
most O
common O
key O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
( O
incidence O
> O
=50 O
% O
) O
were O
hypercholesterolemia B-OSE_Labeled_AE
and O
elevated B-OSE_Labeled_AE
partial I-OSE_Labeled_AE
thromboplastin I-OSE_Labeled_AE
time I-OSE_Labeled_AE
. O

The O
most O
common O
Grade O
3-4 O
laboratory B-NonOSE_AE
abnormality I-NonOSE_AE
( O
incidence O
> O
=3 O
% O
) O
was O
neutropenia B-OSE_Labeled_AE
. O

There O
were O
no O
adverse O
reactions O
resulting O
in O
permanent O
discontinuation O
. O

Dose O
adjustments O
( O
interruptions O
or O
reductions O
) O
due O
to O
adverse O
reactions O
occurred O
in O
55 O
% O
of O
AFINITOR-treated O
patients O
. O

The O
most O
common O
adverse O
reaction O
leading O
to O
AFINITOR O
dose O
adjustment O
was O
stomatitis B-OSE_Labeled_AE
. O

Table O
12 O
compares O
the O
incidence O
of O
adverse O
reactions O
reported O
with O
an O
incidence O
of O
> O
=10 O
% O
for O
patients O
receiving O
AFINITOR O
and O
occurring O
more O
frequently O
with O
AFINITOR O
than O
with O
placebo O
. O

Laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
are O
described O
separately O
in O
Table O
13 O
. O

Table O
12 O
: O
Adverse O
Reactions O
Reported O
in O
> O
= O
10 O
% O
of O
AFINITOR-treated O
Patients O
with O
SEGA O
in O
EXIST-1 O
Grading O
according O
to O
CTCAE O
Version O
3.0 O
a O
Includes O
mouth B-OSE_Labeled_AE
ulceration I-OSE_Labeled_AE
, O
stomatitis B-OSE_Labeled_AE
, O
and O
lip B-OSE_Labeled_AE
ulceration I-OSE_Labeled_AE
b O
Includes O
respiratory B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
and O
respiratory B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
viral I-OSE_Labeled_AE
c O
Includes O
gastroenteritis B-OSE_Labeled_AE
, O
gastroenteritis B-OSE_Labeled_AE
viral I-OSE_Labeled_AE
, O
and O
gastrointestinal B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
d O
Includes O
agitation B-OSE_Labeled_AE
, O
anxiety B-OSE_Labeled_AE
, O
panic B-OSE_Labeled_AE
attack I-OSE_Labeled_AE
, O
aggression B-OSE_Labeled_AE
, O
abnormal B-OSE_Labeled_AE
behavior I-OSE_Labeled_AE
, O
and O
obsessive B-OSE_Labeled_AE
compulsive I-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
e O
Includes O
rash B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
generalized I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
macular I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
maculo I-OSE_Labeled_AE
- I-OSE_Labeled_AE
papular I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
papular I-OSE_Labeled_AE
, O
dermatitis B-OSE_Labeled_AE
allergic I-OSE_Labeled_AE
, O
and O
urticaria B-OSE_Labeled_AE
AFINITOR O
N=78 O
Placebo O
N=39 O
All O
Grades O
% O
Grade O
3 O
% O
Grade O
4 O
% O
All O
Grades O
% O
Grade O
3 O
% O
Grade O
4 O
% O
Any B-NonOSE_AE
adverse I-NonOSE_AE
reaction I-NonOSE_AE
97 O
36 O
3 O
92 O
23 O
3 O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Stomatitis B-OSE_Labeled_AE
a O
62 O
9 O
0 O
26 O
3 O
0 O
Vomiting B-OSE_Labeled_AE
22 O
1 O
0 O
13 O
0 O
0 O
Diarrhea B-OSE_Labeled_AE
17 O
0 O
0 O
5 O
0 O
0 O
Constipation B-OSE_Labeled_AE
10 O
0 O
0 O
3 O
0 O
0 O
Infections B-NonOSE_AE
and I-NonOSE_AE
infestations I-NonOSE_AE
Respiratory B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
b O
31 O
1 O
1 O
23 O
0 O
0 O
Gastroenteritis B-OSE_Labeled_AE
c O
10 O
4 O
1 O
3 O
0 O
0 O
Pharyngitis B-OSE_Labeled_AE
streptococcal I-OSE_Labeled_AE
10 O
0 O
0 O
3 O
0 O
0 O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
Pyrexia B-OSE_Labeled_AE
23 O
6 O
0 O
18 O
3 O
0 O
Fatigue B-OSE_Labeled_AE
14 O
0 O
0 O
3 O
0 O
0 O
Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
Anxiety B-OSE_Labeled_AE
, O
aggression B-OSE_Labeled_AE
or O
other O
behavioral B-OSE_Labeled_AE
disturbance I-OSE_Labeled_AE
d O
21 O
5 O
0 O
3 O
0 O
0 O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Rash B-OSE_Labeled_AE
e O
21 O
0 O
0 O
8 O
0 O
0 O
Acne B-OSE_Labeled_AE
10 O
0 O
0 O
5 O
0 O
0 O
Amenorrhea B-OSE_Labeled_AE
occurred O
in O
17 O
% O
of O
AFINITOR-treated O
females O
aged O
10 O
to O
55 O
years O
( O
3 O
of O
18 O
) O
and O
none O
of O
the O
females O
in O
the O
placebo O
group O
. O

For O
this O
same O
group O
of O
AFINITOR-treated O
females O
, O
the O
following O
menstrual B-OSE_Labeled_AE
abnormalities I-OSE_Labeled_AE
were O
reported O
: O
dysmenorrhea B-OSE_Labeled_AE
( O
6 O
% O
) O
, O
menorrhagia B-OSE_Labeled_AE
( O
6 O
% O
) O
, O
metrorrhagia B-OSE_Labeled_AE
( O
6 O
% O
) O
, O
and O
unspecified B-OSE_Labeled_AE
menstrual I-OSE_Labeled_AE
irregularity I-OSE_Labeled_AE
( O
6 O
% O
) O
. O

The O
following O
additional O
adverse O
reactions O
occurred O
in O
less O
than O
10 O
% O
of O
AFINITOR-treated O
patients O
: O
nausea B-OSE_Labeled_AE
( O
8 O
% O
) O
, O
pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
( O
8 O
% O
) O
, O
insomnia B-OSE_Labeled_AE
( O
6 O
% O
) O
, O
pneumonia B-OSE_Labeled_AE
( O
6 O
% O
) O
, O
epistaxis B-OSE_Labeled_AE
( O
5 O
% O
) O
, O
hypersensitivity B-OSE_Labeled_AE
( O
3 O
% O
) O
, O
increased B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
luteinizing I-OSE_Labeled_AE
hormone I-OSE_Labeled_AE
( I-OSE_Labeled_AE
LH I-OSE_Labeled_AE
) I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
( O
1 O
% O
) O
and O
pneumonitis B-OSE_Labeled_AE
( O
1 O
% O
) O
. O

Table O
13 O
: O
Key O
Laboratory O
Abnormalities O
Reported O
in O
AFINITOR-treated O
Patients O
with O
SEGA O
in O
EXIST-1 O
Grading O
according O
to O
CTCAE O
Version O
3.0 O
AFINITOR O
N=78 O
Placebo O
N=39 O
All O
Grades O
% O
Grade O
3 O
% O
Grade O
4 O
% O
All O
Grades O
% O
Grade O
3 O
% O
Grade O
4 O
% O
Hematology B-NonOSE_AE
Elevated B-OSE_Labeled_AE
partial I-OSE_Labeled_AE
thromboplastin I-OSE_Labeled_AE
time I-OSE_Labeled_AE
72 O
3 O
0 O
44 O
5 O
0 O
Neutropenia B-OSE_Labeled_AE
46 O
9 O
0 O
41 O
3 O
0 O
Anemia B-OSE_Labeled_AE
41 O
0 O
0 O
21 O
0 O
0 O
Clinical B-NonOSE_AE
chemistry I-NonOSE_AE
Hypercholesterolemia B-OSE_Labeled_AE
81 O
0 O
0 O
39 O
0 O
0 O
Elevated B-OSE_Labeled_AE
aspartate I-OSE_Labeled_AE
transaminase I-OSE_Labeled_AE
( I-OSE_Labeled_AE
AST I-OSE_Labeled_AE
) O
33 O
0 O
0 O
0 O
0 O
0 O
Hypertriglyceridemia B-OSE_Labeled_AE
27 O
0 O
0 O
15 O
0 O
0 O
Elevated B-OSE_Labeled_AE
alanine I-OSE_Labeled_AE
transaminase I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
) O
18 O
0 O
0 O
3 O
0 O
0 O
Hypophosphatemia B-OSE_Labeled_AE
9 O
1 O
0 O
3 O
0 O
0 O
Updated O
safety O
information O
from O
111 O
patients O
treated O
with O
AFINITOR O
for O
a O
median O
duration O
of O
47 O
months O
identified O
the O
following O
additional O
notable O
adverse O
reactions O
and O
key O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
: O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
( O
14 O
% O
) O
, O
hyperglycemia B-OSE_Labeled_AE
( O
13 O
% O
) O
, O
hypertension B-OSE_Labeled_AE
( O
11 O
% O
) O
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
9 O
% O
) O
, O
decreased B-OSE_Labeled_AE
fibrinogen I-OSE_Labeled_AE
( O
8 O
% O
) O
, O
cellulitis B-OSE_Labeled_AE
( O
6 O
% O
) O
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
5 O
% O
) O
, O
decreased B-OSE_Labeled_AE
weight I-OSE_Labeled_AE
( O
5 O
% O
) O
, O
elevated B-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
( O
5 O
% O
) O
, O
and O
azospermia B-OSE_Labeled_AE
( O
1 O
% O
) O
. O

6.6 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
post O
approval O
use O
of O
AFINITOR O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
: O
acute B-OSE_Labeled_AE
pancreatitis I-OSE_Labeled_AE
, O
cholecystitis B-OSE_Labeled_AE
, O
cholelithiasis B-OSE_Labeled_AE
, O
arterial B-OSE_Labeled_AE
thrombotic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
, O
reflex B-OSE_Labeled_AE
sympathetic I-OSE_Labeled_AE
dystrophy I-OSE_Labeled_AE
, O
and O
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
with O
some O
cases O
reported O
with O
pulmonary B-NonOSE_AE
hypertension I-NonOSE_AE
( O
including O
pulmonary B-NonOSE_AE
arterial I-NonOSE_AE
hypertension I-NonOSE_AE
) O
as O
a O
secondary O
event O
. O

